Guardant Health is a pioneer in non-invasive cancer diagnostics and the first company to commercialize a comprehensive genomic liquid biopsy.
Transforming cancer care

Our proprietary digital sequencing technology is transforming cancer treatment by providing an accurate and precise picture of the individual genomic alterations that cause tumors to grow, change, and develop resistance to treatment. We have combined decades of scientific research, advances in laboratory technology, and our breakthrough innovation in liquid biopsy to create a test that has already handled tens of thousands of samples.
Tumors evolve, treatment must too

Our current products are just the beginning of what we hope to accomplish, and new uses of our platform are emerging.

Today liquid biopsies are largely a tool for therapy selection for advanced cancers. But some day their utility will cover the entire cancer-care continuum. Liquid biopsies may soon be a tool for early detection, an aid in neoadjuvant and adjuvant therapy, and a non-invasive method for residual disease monitoring and recurrence monitoring.

We know cancer is a dynamic disease and evolves in the face of treatment, and understanding that evolution is critical to developing new treatment plans. We have built a massive database of genomic information about how advanced cancers respond to therapy, which will help us map the paths cancers take when under treatment pressure.

The more detail we add to this map, the better we will understand the disease, and the sooner we can hope to defeat it. We believe this resource can accelerate new drug development and improve the lives of all patients fighting cancer.